Treatment of Bevacizumab and Triamcinolone in Treatment or Macular Edema Secondary to CRVO

Sponsor
Asociación para Evitar la Ceguera en México
Study ID
NCT00566761
Phase
PHASE4
Status
Terminated

Conditions

  • Central Retinal Vein Occlusion
  • Macular Edema

Eligibility Criteria

Sex
ALL
Age
N/A - N/A
Healthy Volunteers
Not accepted

Interventions

  • bevacizumab and triamcinolone — DRUG
    three applications monthly administrated of bevacizumab 2.5mg for group 1 and bevacizumab 2.5 mg + triamcinolone 4mg first dose followed by two of bevacizumab alone for the group 2

Study Details

Treatment of macular edema secondary to central retinal vein occlusion is more effective with combined therapy of bevacizumab and triamcinolone than bevacizumab alone.

Key Dates

First listed
Dec 4, 2007
Start date
Jun 30, 2007
Status verified
May 2024
Primary completion
Jun 30, 2007
Completion
Mar 31, 2008

Study Design

Enrollment
10 participants (actual)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Primary Outcome Measure

Changes in Best corrected visual acuity and macular edema measured with OCT [ Time Frame: Follow up to 3 , 6 and 12 months ]

Related Studies